[Cited FineTest Elisa Kit] Current Research on Liver Cancer Chemotherapy

FineTest Elisa kit contributes to the research on liver cancer chemotherapy. The immunoassay is designed to measure BTC and CCL28 concentration in serum.

Publication Details
Article Title: Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial
Journal Title: European Journal of Cancer
DOI: 10.1016/j.ejca.2022.07.005
IF: 10.002
PMID: 35981413

Abstract: Introduction: The combination of lenvatinib, toripalimab and hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) suggested encouraging antitumour activity in our retrospective study. We hereby prospectively establish the efficacy, safety and predictive biomarkers of the combination therapy as a first-line treatment in patients with high-risk advanced hepatocellular carcinoma (HCC). Materials and methods: This phase II, single-centre, single-arm trial enrolled advanced HCC participants with high-risk. Of 51 screened participants, 36 received lenvatinib, toripalimab plus FOLFOX-HAIC. Participants received 21-day treatment cycles of lenvatinib, toripalimab, and FOLFOX-HAIC. The primary end-point was the progression-free survival (PFS) rate per RECIST at six months. Results: Thirty-six participants (86.1% with high-risk features) were enrolled in our study. The primary end-point was met with a PFS rate of 80.6% (95% CI, 64.0%-91.8%) at six months. The median PFS was 10.4 months (95% CI, 5.8-15.0), and the median OS was not reached at the prespecified final analysis and was 17.9 months (95% CI, 14.5-21.3) after follow-up was extended. The ORR per RECIST was 63.9%, and per mRECIST was 66.7%. The median duration of response was 14.4 months (95% CI, 8.9-19.9). The most common adverse events were thrombocytopenia, elevated aspartate aminotransferase, and hypertension, and no treatment-related death was reported. Participants with low levels of both CCL28 and BTC had unsatisfactory prognosis. Conclusions: Lenvatinib, toripalimab and FOLFOX-HAIC showed safe and encouraging antitumour activity for advanced HCC with high-risk features. The levels of CCL28 and BTC might be the predictive biomarkers for the triple combination therapy.

Keywords: Hepatic arterial infusion chemotherapy; High-risk advanced hepatocellular carcinoma; Lenvatinib; Predictive biomarkers; Toripalimab

Immunoassay

Validated Image

Figure Source: Eur J Cancer. 2022 Aug 15;174:68-77. doi: 10.1016/j.ejca.2022.07.005.

Fig. 4. The levels of CCL28 or BTC before the treatment might be a predictive biomarker for the efficacy of combination therapy. (A) The heatmap of quantitative measurement of human cytokines in the pre-experiment. (B) The change of peripheral blood level of CCL28 (upper) and BTC (lower) before and after the treatment. (C) The expression of PD-1 and lenvatinib target between CCL28 high group and CCL28 low group from TCGA database. (D) Kaplan–Meier curves of overall survival between CCL28 high group and CCL28 low group (cut-off value, 5.9). (E) Kaplan–Meier curves of overall survival between BTC high group and BTC low group (cut-off value, 387.8). (F) Kaplan–Meier curves of overall survival between CCL28^lowBTC^low group and non-CCL28^lowBTC^low group. (G) The number of CD8⁺ (left) and CD4⁺ (right) T cells before and after the treatment.